PBMs and health insurers decide what medicines you can get, and they set the price you pay at the pharmacy. At the same time, over half of every dollar spent on medicines goes to these middlemen and others. Find out more: https://lnkd.in/e2eY5jCz
PhRMA
Pharmaceutical Manufacturing
Washington, DC 57,264 followers
Research. Progress. Hope.
About us
Our Mission: The Pharmaceutical Research & Manufacturers of America (PhRMA) has as its mission to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical and biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving these goals in Washington, the states and the world: Broad patient access to safe and effective medicines through a free market, without price controls; Strong intellectual property incentives; And transparent, effective regulation and a free flow of information to patients. Who We Are: The Pharmaceutical Research and Manufacturers of America (PhRMA) represents innovative biopharmaceutical research and discovery companies. PhRMA is devoted to advancing public policies in the U.S. and around the world that support innovative medical research, yield progress for patients today and provide hope for the treatments and cures of tomorrow. Key Facts about the Biopharmaceutical Industry: - Since 2000, PhRMA member companies have invested more than $900 billion in the search for new treatments and cures. - America’s biopharmaceutical industry is the global leader in medical innovation, with more than 500 new medicines approved by the Food and Drug Administration since 2000. - The biopharmaceutical pipeline has over 7,000 new medicines currently in development around the world. Get fresh content daily by subscribing to our updates at https://catalyst.phrma.org/subscribe
- Website
-
https://www.PhRMA.org
External link for PhRMA
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Washington, DC
- Type
- Nonprofit
- Founded
- 1958
- Specialties
- Policy, Scientific Research, Advocacy, Public Affairs, Federal Affairs, State Government Affairs, and pharmaceuticals
Locations
-
Primary
950 F Street, NW
Suite 300
Washington, DC 20004, US
Employees at PhRMA
Updates
-
40 years ago, Congress passed the #HatchWaxmanAct, a bipartisan law that laid the foundation for biopharmaceutical competition. This month, we’ll be sharing more about the bill, how it helps patients and how we can build upon its success.
-
Despite claims Medicare Part B inflation rebates are lowering out-of-pocket medicine costs for patients, new Avalere data show the real story: More than 99% of traditional Medicare patients aren’t seeing lower costs on their Part B medicines. Learn more: https://lnkd.in/eSXxSQq3
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
phrma.org
-
A new study, conducted by researchers at Johnson & Johnson, Harvard University and Analysis Group, demonstrates how biopharmaceutical companies headquartered in the U.S. are at the forefront of research and development, paving the way for innovative medicines and treatments. Here’s how biopharmaceutical companies are leading the charge in tackling society’s most pressing health care challenges: - Biopharmaceutical companies are investing in R&D at an immense, global scale – and at significant spend. - U.S.-based biopharmaceutical companies lead the global research race in a competitive industry landscape, representing nearly half of all global biopharmaceutical companies and providing almost twice as much worldwide R&D as European companies. For additional insights, check out our blog: https://lnkd.in/eEnfZDHH Read the full analysis here: https://lnkd.in/eYQNj8tb
New research: American biopharmaceutical investment in R&D drives transformational innovation
phrma.org
-
Amgen and Merck, renowned for their commitment to health care innovation, have partnered with Equitable Breakthroughs in Medicine Development to drive meaningful progress in clinical trial research. Together, they will pioneer novel strategies to foster closer collaboration and engagement with local trial sites and communities. Learn more about the PhRMA-funded initiative to advance equity in clinical trials: https://lnkd.in/er4uYQEN
-
American Enterprise Institute Nonresident Fellow Kirsten Axelsen highlights how the Inflation Reduction Act’s unintended consequences threaten oncology innovation.
-
PhRMA is excited to join the Congressional Black Caucus for their Annual Legislative Conference this week! Featuring Representative Jasmine Crockett, Anthony Coley (Founding Partner, Corner Office Strategies), Tesheia Johnson (EQBMED Network Partner Leader), Reverend Dr. Leroy O. Perry Jr. (EQBMED Trusted Messenger) and Darryl Sleep, MD (MBBCh, FCS(SA)) (Head of Global Public Health, Amgen), our panel will focus on how policies can better protect patients and examine how we can enhance access to clinical trials in communities of color and for rural residents. Addressing shortcomings and highlighting the progress necessary for an equitable future, the conversation will demonstrate the importance of partnering with communities to realize meaningful health care solutions for all patients. Join us on Thursday, September 12 from 3-4pm in Room 146B. #ALC53
-
A study from JAMA Health Forum shows how the United States saw the largest drop in medicine prices after a #patent expires and generic medicines were introduced, compared to several other countries. This is only possible because of a strong #IP system that leads to more innovation and generic medicine options. https://lnkd.in/dQUBga3K
Patent Expirations and Drug Prices in High-Income Countries
jamanetwork.com
-
Thinking about a career in STEM? Inspired by the potential to innovate lifesaving therapeutics? Join us at our Virtual STEM Career Expo to connect with leading biopharma companies. We’ll host info sessions throughout the day, providing information on the skills and qualities top companies look for in #STEM candidates. Register for free: https://lnkd.in/gjRuqqAc
-
Each day, biopharmaceutical researchers work to make new discoveries to address today’s most challenging diseases. Here, Eli Lilly and Company’s Ying Tang shares the importance of policies that support this research pipeline.